Doctiplus - We are allways here!
Dementia & Alzheimer's
Weekly Report
- 10 new clinical trials registered across 7 countries.
- 964 trials actively recruiting patients worldwide.
- Notable trial: A Study of Urine Volatile Organic Compounds for Disease Detection (30000 patients).
- 1,314 new research papers published.
- Top cited: "Annual Wellness Visits and Timing of Advance Care Planning Among Medicare Beneficiaries With Cogn..." (Journal of the American Geriatrics Society, 2 citations).
- Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
10 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | Impact of External Workplace Violence on the Occupational Well-being of Healthcare Workers Dementia & Alzheimer's · Consorci Sanitari de l'Alt Penedès i Garraf (NCT07926802) | Other | Recruiting | 442 | Spain |
| 02 | Acoustic Stimulation During Sleep for Alzheimer's Disease Dementia & Alzheimer's · Xuanwu Hospital, Beijing (NCT07924657) | Other | Recruiting | 40 | China |
| 03 | 40 Hz Audio-Visual Stimulation Therapy for AD Dementia & Alzheimer's · The First Affiliated Hospital of Xiamen University (NCT07926438) | Other | Not Yet Recruiting | 50 | China |
| 04 | Aggression in Military Personnel Dementia & Alzheimer's · James A. Haley Veterans Administration Hospital (NCT07931079) | Other | Not Yet Recruiting | 106 | N/A |
| 05 | A Study of Urine Volatile Organic Compounds for Disease Detection Dementia & Alzheimer's · Toby, Inc. (NCT07933042) | Other | Not Yet Recruiting | 30,000 | N/A |
| 06 | Wearable HRV Biofeedback for Stress in Dementia Caregivers Dementia & Alzheimer's · Instituto de Investigación Marqués de Valdecilla (NCT07930364) | Other | Recruiting | 100 | Spain |
| 07 | Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias Dementia & Alzheimer's · Rhode Island Hospital (NCT07933367) | Other | Not Yet Recruiting | 280 | United States |
| 08 | Implementing Brain Health PRO Across Diverse Settings: A Multi-Site Implementation Study Dementia & Alzheimer's · Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal (NCT07935629) | Other | Recruiting | 434 | Canada |
| 09 | Virtual Reality vs. Gym-Based Martial Arts Training for Aggression in Children With Conduct Disorder Dementia & Alzheimer's · Islamic Azad University, Sanandaj (NCT07929025) | Other | Completed | 306 | Iran |
| 10 | Cardiovascular And Dementia Risk in diabeTes: the Role of Nox2- Related Oxidative Stress. Dementia & Alzheimer's · Neuromed IRCCS (NCT07928453) | Other | Recruiting | 250 | Italy |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| donepezil | Death | 208 |
| memantine | Death | 129 |
| rivastigmine | Death | 292 |
| galantamine | Fall | 32 |
| lecanemab | Amyloid Related Imaging Abnormality-oedema/effusion | 204 |
Recalls & safety notices
FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Dietary Sugar Intake and Risk of Cognitive Disorders: A Systematic Review and Meta-Analysis.
View abstractCONTEXT: Although prior studies have linked excessive dietary sugar intake to adverse cognitive outcomes, the findings of individual studies remain inconsistent, and there is a lack of synthesis. OBJECTIVE: The objective of this study was to comprehensively examine the association between dietary sugar intake and risk of cognitive disorders. DATA SOURCES: The Cochrane, Embase, PubMed, ScienceDirect, and Web of Science databases were searched from inception to December 2025. DATA EXTRACTION: Prospective cohort, nested case-control or case-cohort studies evaluating the association of dietary total sugar or its subtypes with the risk of cognitive disorders, including cognitive impairment and dementia (including Alzheimer's disease), in adults were reviewed. Details of the studies and main outcomes were extracted independently by 2 reviewers. DATA ANALYSIS: Among 2171 records screened, 10 prospective cohort studies comprising 12 cohorts and 257 761 participants were included. The number of cohorts and participants for each exposure was as follows: total sugar: 5 (N = 200 812); sugar-sweetened beverages: 9 (N = 214 084); fruit juice: 2 (N = 194 847); fructose: 4 (N = 197 082); sucrose: 3 (N = 194 928); lactose: 3 (N = 194 928); maltose: 3 (N = 194 928); glucose: 3 (N = 194 928). Meta-analysis indicated that individuals with the highest total sugar intake were at a higher risk of cognitive disorders compared with those with the lowest intake (hazard ratio = 1.23, 95% CI = 1.10-1.38, low certainty). No significant associations were observed for any specific sugar subtypes examined, with certainty of evidence ranging from low to very low. CONCLUSIONS: The present review suggests that higher total sugar intake may be associated with an increased risk of cognitive disorders. In contrast, the current evidence does not support a clear association between specific sugar subtypes and cognitive disorders. Future studies should prioritize clarifying the dose-response relationship between total sugar intake and cognitive disorders. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42025640308. |
Nutrition reviews | 2026 Nov 15 | PubMed |
| 02 |
[Assessment of neurocognitive decline in primary care practice].
View abstractINTRODUCTION: Neurocognitive disorders pose a significant public health burden but often remain undetected at an early stage. Since several risk factors are modifiable, primary care plays a crucial role in prevention, screening, and management. OBJECTIVE: This study investigated the prevalence of cognitive decline and its associated demographic, lifestyle, health, and digital factors among patients aged 65 and older in a general practitioner practice in Budapest. METHOD: This cross-sectional study included 214 adult patients. Cognitive performance was measured using the education-adjusted Montreal Cognitive Assessment. Mood symptoms were assessed via the Hospital Anxiety and Depression Scale, while sociodemographic, lifestyle, health, and digital habits were recorded using a self-administered questionnaire. Data were analyzed using Spearman's rank correlation. RESULTS: The participants' mean age was 75.8 ± 7.2 years; 66.8% were women, and 59.8% held a college degree. The mean Montreal Cognitive Assessment score was 26.6 ± 2.5. Suspected cognitive impairment was identified in 29.9% of participants using the standard <26 cutoff, and in 9.4% using a stricter <24 cutoff. Montreal Cognitive Assessment scores correlated negatively with age, but showed significant positive associations with mobility, self-care, quality of life, better mood, good general health, subjective cognitive assessment, and daily digital device use (p<0.05). Education and chronic disease count showed no significant associations. DISCUSSION: Early-stage neurocognitive decline is highly prevalent in general practice and requires structured screening to be detected. The significant links between cognitive performance and functional, lifestyle, and digital factors highlight the necessity of a multifactorial approach. CONCLUSION: The Montreal Cognitive Assessment is an effective primary care screening tool. Our results emphasize the importance of comprehensive, lifestyle-oriented prevention. The link between digital device use and cognition could inspire computer-based screening, monitoring and training programs in primary care. Orv Hetil. 2026; 167(46): 1867-1875. |
Orvosi hetilap | 2026 Nov 15 | PubMed |
| 03 |
Substituent effects on electronic properties and predicted acetylcholinesterase binding potential of donepezil analogues: a DFT, molecular docking, and ADMET study with dynamics assessment of the lead candidate.
View abstractUNLABELLED: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common cause of dementia in older people. Donepezil is an acetylcholinesterase inhibitor used for symptomatic management of AD. Due to its clinically established AChE inhibition; it was used as a reference. In this study, a series of donepezil derivatives were designed by introducing a para substituent (NH, NO, Cl, OH or OCH) on the benzyl moiety and systematically investigated along with the using density functional theory, time-dependent DFT, molecular docking, and in silico pharmacokinetics analysis. The geometry optimization and electronic structure calculations were performed using the B3LYP/6-311G (d, p) level. Frontier molecular orbital analysis indicated reduced energy gaps in and . The in silico molecular docking analysis of all derivatives and the was performed against the acetylcholinesterase receptor (PDB ID 4EY7), where , and showed Vina scores equal to the (- 12.2 kcal/mol). was selected for a single 300 ns molecular dynamics simulation (unlike MH-1 and MH-2, it had no predicted mutagenicity alert). The protein backbone RMSD stayed mostly between 0.15 and 0.22 nm, and the ligand stayed in contact with the protein while changing its conformation and orientation. MM-GBSA enthalpy was stable across sampling densities (ΔH ≈ -24.6 kcal/mol), whereas the Interaction Entropy-corrected binding free energy varied with the number of frames analysed (ΔG = - 9.76 to - 15.71 kcal/mol, standard error ≈ 3.7-4.0 kcal/mol). Moreover, ADMETlab 3.0 predicted high intestinal absorption. ProTox 3.0 predicted several toxicity alerts for all compounds, including immunotoxicity and respiratory toxicity; and were also flagged for mutagenicity. In summary, is proposed as a candidate for experimental evaluation. All results are computational predictions and require experimental validation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00786-2. |
In silico pharmacology | 2026 | PubMed |
| 04 |
Plasma biomarker signatures in patients with rapidly progressive dementia.
View abstractINTRODUCTION: Overlapping clinical features and results of common diagnostic tests confound early, accurate recognition of distinct causes of rapidly progressive dementia (RPD). Objective, accessible tools are needed to improve etiologic diagnoses and inform counseling and treatment decisions. METHODS: Biomarkers of Alzheimer's disease neuropathology, neuroaxonal injury, neuroinflammation, vascular injury, metabolic dysfunction, and systemic inflammation were measured in plasma from 58 patients with RPD and 40 patients with typically progressive neurodegenerative diseases enrolled in prospective studies of memory and aging. RESULTS: Neuroaxonal injury and neuroinflammation biomarkers were elevated in patients with prion and vascular (versus other) causes of RPD. Markers of systemic inflammation were uniquely elevated in patients with rapidly versus typically progressive neurodegenerative diseases. Higher phosphorylated tau (p-tau)217 and p-tau181 levels, and lower amyloid beta 42/40 levels, were nominally associated with treatment-non-responsive causes of RPD. DISCUSSION: Blood biomarkers may inform biological heterogeneity underlying RPD with potential diagnostic and therapeutic implications pending validation in larger longitudinal cohorts. |
Alzheimer's & dementia (Amsterdam, Netherlands) | 2026 Oct-Dec | PubMed |
| 05 | Corrigendum to "CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis" [Ageing Res. Rev. 101 (2024) 102485]. | Ageing research reviews | 2026 Nov 14 | PubMed |
| 06 |
Case Study on Nursing Pain Interpretation and Residents' Ability to be Understood.
View abstractINTRODUCTION: In long term care [LTC], the high prevalence of painful illnesses and dementia contributes to complex care needs and challenging pain management. What further complicates matters for residents in this context is the inability to be understood. PURPOSE: In addition to not being understood in the expression of their pain, many residents with a cognitive impairment will exhibit behavioral and psychological symptoms of dementia [BPSDs]. Pain indicators may then resemble BPSDs and be interpreted and treated as such. Little is known about this interpretation and subsequent interventions by nurses. DESIGN: To explore the management of pain in the LTC context, a single-site retrospective case-study was conducted in a Canadian province using a predefined list of indicators drawn from validated observational pain assessment instruments and the pain literature. METHODS: These indicators guided the review of residents' charts by abstracting data from nursing documentation and medication administration records. Nursing interpretation of symptoms, as documented in their notes, as either pain or behavior, as well as their actions, were examined. Also explored were associations between the resident's ability to be understood and the nursing interpretation of their symptoms. RESULTS: The analysis discovered that many symptoms were more likely to be interpreted as behavior versus pain. Furthermore, a relationship was discovered between the resident's ability to be understood and the interpretation of some symptoms as behavior versus pain. CONCLUSIONS AND CLINICAL IMPLICATIONS: Recommendations are made to better support nurses with this important yet challenging role of pain and behavior interpretation with residents who cannot be understood. |
Pain management nursing : official journal of the American Society of Pain Management Nurses | 2026 Nov 14 | PubMed |
| 07 |
A hypothesis framework linking the menopausal transition, sleep and brain waste clearance: Insights from experimental models.
View abstractThe menopausal transition is increasingly recognized as a neuroendocrine transition with implications for brain health, sleep, cognition and vulnerability to neurodegenerative disease. Fluctuating and declining ovarian hormones coincide with sleep disruption, vasomotor symptoms, cognitive complaints, neuroinflammation and altered blood-brain barrier integrity. Current preclinical models each capture selected components of the menopause transition and provide essential mechanistic insights into the effect of ovarian hormone loss on the brain. Across these models, endocrine change is associated with impairments in hippocampal and prefrontal-dependent cognition, altered sleep-wake regulation, vascular dysfunction, glial activation, disrupted synaptic and mitochondrial homeostasis and exacerbation of Alzheimer's and Parkinson's disease-like pathology. An emerging but understudied mechanism linking menopause, sleep and neurodegeneration is the glymphatic system, a sleep-dependent brain waste clearance pathway. This review synthesises current evidence to highlight how menopause-related sleep disruption, vascular dysfunction, neuroinflammation and potential alterations in brain-waste clearance may converge to shape cognitive ageing and neurodegenerative disease risk. |
Frontiers in neuroendocrinology | 2026 Nov 14 | PubMed |
| 08 |
DEGORA: turning heterogeneous published DEG summaries into an inspectable gene-evidence atlas.
View abstractPublished tables of differentially expressed genes (DEG tables) can support secondary transcriptomic analyses when expression matrices or variance estimates are unavailable, but they are not consistently deposited in public repositories. DEGORA converts curated DEG tables into a local database that links gene-level evidence to original studies. It standardizes gene identifiers, collapses related contrasts within studies so that each study contributes once, applies fixed heuristic quality weights, and ranks genes by cross-study support and directional concordance. An optional search module identifies potentially reusable tables. We evaluated DEGORA using four human transcriptional programs as positive-control benchmarks, each represented by 2 to 15 publication-level source units and by up to 20 after human microarray sources were added. DEG tables for three programs were generated from publicly available count matrices, whereas those for the fourth were obtained from the original publications. Using RNA-seq evidence, DEGORA recovered 93% of interferon, 59% of endoplasmic reticulum stress, 73% of heat-shock, and 85% of hypoxia markers among the top 100 ranked genes. In three confirmatory datasets, DEGORA showed no consistent ranking advantage over alternative methods applied to the same tables. The same workflow organized published Alzheimer's disease cohort evidence without recomputing differential expression. Across ten evaluated datasets, performance varied with how the input tables were generated. Overall, DEGORA organizes differential expression evidence at the study level and keeps every ranked gene linked to the publications, assays, and reported statistics behind it. |
Methods (San Diego, Calif.) | 2026 Nov 14 | PubMed |
| 09 |
EEG Microstate Alterations and Their Association with Cognitive Performance in Late-Onset Epilepsy of Unknown Etiology: Comparison with Alzheimer's Disease.
View abstractBACKGROUND: Cognitive impairment is common in late-onset epilepsy of unknown etiology (LOEU), but its electrophysiological correlates and relationship to Alzheimer's disease (AD) remain unclear. We compared resting-state electroencephalogram (EEG) microstate dynamics among LOEU, AD, and cognitively normal (CN) groups and examined their associations with cognitive performance. METHODS: Eyes-closed 32-channel resting-state EEG recordings were analyzed from 60 patients with LOEU, 65 with AD, and 60 CN participants. Four canonical microstate classes (A-D) were identified. Group differences in microstate parameters were tested with false discovery rate correction. Associations with Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) scores were examined using multivariable interaction models adjusted for age, sex, education, and cerebral small vessel disease burden. RESULTS: Microstate B duration was longer in LOEU and AD than in CN (Holm-adjusted p=0.011 and 0.016), whereas microstate C occurrence was lower in both patient groups (p=0.001 and 0.018). Microstate D duration was longer in LOEU than in CN and AD (both p=0.038). For microstate A duration, the group interaction survived false discovery rate correction for MMSE (q=0.0255) but not MoCA (q=0.122). In LOEU, longer microstate A duration was associated with lower MoCA and MMSE scores. Pairwise slope comparisons were more negative in LOEU than in CN for both outcomes, whereas LOEU-AD slope differences were not significant. CONCLUSIONS: LOEU showed altered resting-state EEG microstate dynamics that partly overlapped with those observed in AD, alongside a group difference in microstate D duration. Microstate A duration was associated with cognitive performance in LOEU, although this association did not significantly differ from that observed in AD. These findings support further investigation of EEG microstates as electrophysiological correlates of cognitive dysfunction in LOEU while also highlighting overlap with AD. |
Brain research bulletin | 2026 Nov 14 | PubMed |
| 10 |
Identification of mitophagy inducers for Alzheimer's disease via high-throughput endogenous ATP5B tagging system.
View abstractINTRODUCTION: Mitophagy, the selective clearance of defective mitochondria via the autophagy-lysosome pathway, is essential for maintaining mitochondrial health and cellular homeostasis. Dysregulation of mitophagy is strongly implicated in aging-related pathologies, including neurodegenerative diseases (Alzheimer's, Parkinson's), cancer, and metabolic disorders, highlighting the significance of elucidating its regulatory mechanisms. While existing methods using exogenous reporters enable genome-wide and high-throughput screening for mitophagy regulators, they constrain discoveries to specific pathways and introduce artifacts through ectopic expression. OBJECTIVES: To overcome these limitations, we developed an effective and rapid platform for identifying mitophagy modulators by targeting endogenous proteins. METHODS: Using CRISPR-Cas9 technology, we engineered HeLa cells expressing small molecular tags (GFP or NanoLuc) fused to the C-terminal of ATP5B, a mitochondrial inner membrane protein. Genome-wide screening for mitophagy regulatory genes were performed using a genome-wide CRISPR library coupled with flow cytometry. Additionally, an FDA-approved kinase inhibitor library was used to screen for mitophagy inducers. To evaluate the efficacy of a screened drug in Alzheimer's disease, cognitive behavior, pathological features and mitophagy events in 3 × Tg-AD mice with or without treatment were examined using the Morris water maze assay, enzyme-linked immunosorbent assay (ELISA) and transmission electron microscopy (TEM). RESULTS: These ATP5B-tagging cells provided a robust readout of mitophagy and enabled high-throughput genetic or pharmacological screening. With this platform, we identified several promising genes that regulate mitophagy and are significantly associated with Alzheimer's disease. Moreover, the FDA-approved drug Flupentixol emerged as a novel mitophagy inducer that acts by promoting adenosine monophosphate-activated protein kinase (AMPK) localization to mitochondria and exhibited strong therapeutic potential in a model of Alzheimer's disease. CONCLUSION: This study establishes a novel system for identifying mitophagy modulators, with the potential to accelerate the discovery of therapeutic strategies for Alzheimer's disease. |
Journal of advanced research | 2026 Nov 14 | PubMed |
| 11 |
LifespanFix: Semi-supervised cortical correction across the human lifespan.
View abstractAccurate characterization of the cerebral cortex in brain magnetic resonance imaging (MRI) is essential for reliable morphometric analyses across the human lifespan. However, the cortex's thin and highly convoluted architecture, together with imaging artifacts, frequently introduces topological and anatomical defects in segmentation that can bias downstream analyses. Here we present LifespanFix, a lifespan-robust cortical correction model that directly fixes topological and anatomical defects in segmentation. Specifically, we develop a semi-supervised framework in which a generation network produces template-constrained pseudo-labels that serve as structurally plausible targets for training a correction network (LifespanFix). During inference, only the trained LifespanFix model is deployed, enabling efficient end-to-end correction of cortical defects without requiring the generation network or the time-intensive registration used during training. Our framework was trained on 3,189 subjects spanning the human lifespan - from infancy to older adulthood - across nine public datasets. For evaluation, we assembled an independent lifespan testing cohort comprising 1,058 subjects from five datasets, including label maps generated by different segmentation methods. LifespanFix consistently outperforms state-of-the-art correction approaches, producing more accurate and anatomically plausible cortical segmentations across diverse ages, scanners, and imaging protocols, thereby enabling more reliable large-scale lifespan neuroimaging analyses. |
Medical image analysis | 2026 Nov 12 | PubMed |
| 12 |
Structured home-based interventions for people with dementia: A systematic review and meta-analysis.
View abstractBACKGROUND: Dementia is a progressive neurodegenerative disorder causing cognitive decline and behavioral and psychological symptoms (BPSD), burdening patients and caregivers. Pharmacological treatments have limited efficacy and side effects, highlighting the need for non-pharmacological strategies. AIM: To evaluate the effects of Structured Home-based Interventions on cognitive function and neuropsychiatric symptoms-including overall BPSD, anxiety, and depression-in people with dementia. METHODS: Following PRISMA, we searched PubMed, Embase, Cochrane Library, Web of Science, and four Chinese databases from inception to October 24, 2025, for randomized controlled trials comparing Structured Home-based Interventions with usual care or wait-list controls. Quality was assessed using RoB 2.0; random-effects meta-analyses used Stata 18.0. RESULTS: Thirty-five RCTs (N > 5,000) were included. Structured Home-based Interventions improved cognition (SMD = 0.82, 95% CI: 0.54 to 1.10, P < 0.001), with integrated multicomponent and cognitively oriented interventions showing the largest effects. Overall neuropsychiatric symptoms showed a small reduction (SMD = -0.18, 95% CI: -0.34 to -0.01, P < 0.05). Anxiety (SMD = -1.15, 95% CI: -2.29 to -0.01) and depression (SMD = -0.76, 95% CI: -1.40 to -0.12) improved more, but heterogeneity and limited robustness warrant caution. CONCLUSION: These findings suggest the potential value of Structured Home-based Interventions, especially integrated multicomponent models, and may inform future community dementia services. However, given substantial heterogeneity, limited robustness for some outcomes, and very low certainty of evidence for anxiety and depressive symptoms, broad implementation requires caution, and further validation is warranted. Nurses may play a key role in training family caregivers. PROSPERO: CRD420251178386. |
Geriatric nursing (New York, N.Y.) | 2026 Nov 14 | PubMed |
| 13 |
Remembrance and Personhood in Dementia: Relational Futures of Reminiscence in Poland and the United States.
View abstractDrawing on ethnographic research among persons with dementia in Poland and the US, this article examines temporal and affective elements of reminiscence activities via their relational and material emergence. As a type of person-centered care, reminiscence aims to create coherent, continuous personhood through focusing on positive memories, which have generational and gendered dimensions. In practice, these activities create futures with multivalent affective elements that do not rely on continuity. This article uses kinship-studies and critical phenomenological lenses to show that reminiscence can both open and constrain possibilities for personhood in dementia in ways that highlight its political and moral aspects. |
Medical anthropology | 2026 Nov 14 | PubMed |
| 14 |
Multilayer Transcriptomic Analysis Prioritizes RAE1 and SLC25A46 as Alzheimer's Disease Candidate Genes Related to Nucleocytoplasmic Transport and Mitochondrial Homeostasis.
View abstractRegional and cellular heterogeneity complicates transcriptomic candidate prioritization in Alzheimer's disease (AD). We integrated donor-adjusted differential expression, exploratory co-expression analysis, donor-grouped nested machine learning, external evaluation, and single-nucleus and spatial localization. Differential screening used false discovery rate < 0.05 and absolute log2 fold change > 0.10. We also examined functional enrichment, immune context, pseudotime, cell communication, virtual knockout, and exploratory compound screening and docking. Among 173 tissue samples from 63 donors, 356 genes met the screening criteria; 44 of 113 algorithm combinations yielded complete evaluations. RAE1 was downregulated across four discovery regions and both external cohorts, with areas under the receiver operating characteristic curve (AUC) of 0.662 (95% confidence interval 0.429-0.894) and 0.863 (0.693-1.000). The frozen Stepglm[forward] model yielded external AUCs of 0.5154 and 0.8875. SLC25A46 showed opposite discovery and external expression directions. Genome-wide enrichment identified 754 Gene Ontology terms and 62 Kyoto Encyclopedia of Genes and Genomes pathways, including negatively enriched mitochondrial energy and RNA-processing programs. Localization across 61,472 nuclei and 25,293 spatial spots, together with virtual perturbation, defined cellular contexts. R-547, JNJ-7,706,621, and roscovitine provided single-engine docking leads. These findings prioritize RAE1 for nucleocytoplasmic RNA-transport research and SLC25A46 as a context-dependent mitochondrial-homeostasis candidate. The compound results provide leads for target-binding and cellular functional studies. |
Journal of molecular neuroscience : MN | 2026 Nov 14 | PubMed |
| 15 |
Identification of Key Fatty acid Metabolism-Related Genes in Vascular Dementia.
View abstractVascular dementia (VaD) is a progressive neurodegenerative disorder characterized by chronic cerebral hypoperfusion and cognitive decline, yet the role of fatty acid metabolism in its pathogenesis remains incompletely understood. Integrated transcriptomic profiling was combined with network-based analysis, weighted gene co-expression network analysis (WGCNA) and machine learning to uncover key fatty acid metabolism-associated molecular features associated with VaD. Single-cell RNA sequencing, intercellular communication inference, and in silico perturbation analyses were applied to define immune-stromal interactions. Potential therapeutic compounds were evaluated using molecular docking and dynamics simulations. We identified three VaD-related fatty acid metabolism genes (VaD-FAMRGs), namely PNPLA3, HSP90AA1, and ALB, which showed consistent diagnostic performance across multiple computational approaches and were associated with lipid metabolism, inflammatory processes, and neurovascular unit dysfunction. Functional enrichment, single-cell RNA sequencing, and in silico gene perturbation analyses provided exploratory insights into the potential associations of these candidate genes with lipid transport, metabolic regulation, synaptic maintenance, and immune-inflammatory processes. Cell-cell communication analysis further revealed activation of the ANGPTL signaling axis, suggesting impaired endothelial-glial interactions driven by lipid metabolic dysregulation. Regulatory network analysis identified key transcriptional and post-transcriptional regulators, including REST, miR-155-5p, and miR-21-5p, which may coordinately modulate VaD-FAMRG expression. Drug repurposing analysis highlighted quercetin as a candidate compound with predicted interactions with all three hub proteins, supported by molecular docking and molecular dynamics simulations. These findings suggest that dysregulated fatty acid metabolism may be associated with the development and progression of VaD through coordinated metabolic, inflammatory, and neurovascular mechanisms. This study provides a systems-level framework for understanding the underlying pathological processes and establishes a theoretical basis for future mechanistic and experimental validation. |
Journal of molecular neuroscience : MN | 2026 Nov 14 | PubMed |
| 16 |
Neuropharmacology of omega-3 long-chain polyunsaturated fatty acids in neurodegenerative diseases: mechanisms, multi-omics evidence, and clinical translation.
View abstractNeurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, involve progressive neuronal dysfunction associated with neuroinflammation, oxidative stress, mitochondrial impairment, defective proteostasis, and synaptic failure. Although symptomatic treatment remains central, anti-amyloid therapies can modestly slow clinical decline in selected patients with early Alzheimer's disease. This review critically evaluates the neuropharmacological evidence for omega-3 long-chain polyunsaturated fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and the barriers to their clinical translation. We narratively synthesized preclinical, observational, and interventional clinical evidence, focusing on membrane organization, inflammatory resolution, mitochondrial and redox homeostasis, autophagy, proteostasis, neuronal signaling, and factors contributing to heterogeneous clinical outcomes. Preclinical studies support context-dependent effects of DHA and EPA on neuronal membranes, inflammatory signaling, mitochondrial function, redox balance, autophagy, and synaptic plasticity. Human evidence is less consistent: observational studies generally report favorable associations between omega-3 status and neurological outcomes, whereas randomized trials show null, modest, or subgroup-dependent effects. Outcomes vary with disease stage, baseline omega-3 status, formulation, dose, treatment duration, genotype, and endpoint selection. Uncertain central nervous system exposure and limited pharmacokinetic and target-engagement data remain major translational barriers. Omega-3 long-chain polyunsaturated fatty acids are biologically plausible neuropharmacological modulators, but current evidence does not establish DHA or EPA as broadly effective disease-modifying treatments for neurodegenerative diseases. Future trials should prioritize early-stage, biomarker-stratified populations, pharmacologically characterized formulations, adequate treatment duration, and clinically meaningful progression-related outcomes. |
Naunyn-Schmiedeberg's archives of pharmacology | 2026 Nov 14 | PubMed |
| 17 |
Fixel-based analysis identifies selective vulnerability of non-dominant fiber populations in aging and mild cognitive impairment.
View abstractFixel-based analysis (FBA) resolves fiber-specific white matter properties within crossing-fiber regions, where conventional diffusion tensor imaging is limited. We applied single-shell three-tissue constrained spherical deconvolution to diffusion MRI from 295 older adults in the Vanderbilt Memory and Aging Project cohort, quantifying fiber density (FD), fiber-bundle cross-section (FC), and their composite (FDC) across the primary (N1), secondary (N2), and tertiary (N3) fiber populations within each white matter voxel. White matter was stratified into crossing-fiber complexity strata defined by the number of distinct bundles per voxel, and covariate-adjusted models examined associations with age, cognitive status, and cognition. FC declined with age most steeply in the non-dominant fiber populations. In these populations, FC was lower in participants with mild cognitive impairment than in cognitively unimpaired participants, and higher FC was associated with better executive function. The age-related decline in non-dominant FC did not vary across crossing-fiber complexity, indicating that fiber-population identity, rather than local architecture, organizes age-related vulnerability. FD and FDC showed age associations that became more positive as complexity increased, with the N1 FD association reversing from negative in the least complex regions to positive in the most complex. This behavior is consistent with how density is estimated in multi-fiber voxels rather than with fiber loss, identifying FC as the more interpretable metric in crossing-fiber regions. These findings identify fiber cross-section in the non-dominant fiber populations as a sensitive marker of white matter aging and cognitive status and provide a framework for fiber-specific analysis in existing single-shell cohorts. |
Brain structure & function | 2026 Nov 14 | PubMed |
| 18 |
Association between Brain Amyloid Status and Cognitive and Physical Performance in Older Adults with Frailty Criteria: Longitudinal Data from the CogFrail Study.
View abstractBACKGROUND: The impact of cerebral amyloid pathology on cognitive and functional decline may differ with age. Evidence linking brain amyloidopathy to physical decline remains limited and inconsistent. This study investigated the association between brain amyloid status and cognitive and physical decline in (pre)frail older adults with cognitive impairment. METHODS: This longitudinal analysis used data from the CogFrail study. Brain amyloid pathology was assessed using amyloid-positron emission tomography (visual reading). Linear mixed-effects models examined differences over a two-year follow-up between amyloid-positive and amyloid-negative participants in cognitive, functional, and physical trajectories. Cognitive and functional outcomes included the Mini-Mental State Examination, the Clinical Dementia Rating-Sum of Boxes, the Activities of Daily Living Index, and a neuropsychological battery, while the physical domain was assessed using handgrip strength, chair rise time, gait speed, and the Short Physical Performance Battery. RESULTS: Among 199 participants (mean age 82.3 ± 4.8 years; 65.3% women), 108(54.3%) were amyloid-positive. Amyloid-positive participants experienced greater decline in the Clinical Dementia Rating-Sum of Boxes (β = 0.30, 95% CI 0.10-0.49; p = 0.003, log-transformed) and the Mini-Mental State Examination (β = -1.62, 95% CI -2.74 to -0.49; p = 0.005). No significant longitudinal differences were observed between groups in the Activities of Daily Living Index, neuropsychological outcomes, or physical performance measures. CONCLUSION: Amyloid pathology assessment may help differentiate cognitive trajectories in cognitively impaired (pre)frail older adults. Greater cognitive decline in amyloid-positive participants was not associated with greater loss of independence or additional physical decline over time. TRIAL REGISTRATION: NCT03129269. |
The journals of gerontology. Series A, Biological sciences and medical sciences | 2026 Nov 14 | PubMed |
| 19 |
Cultural Adaptation of an Intervention Guide for a Non-pharmacological Palliative Care Intervention for People With Advanced Dementia: A Multi-Stakeholder Process Preparatory to the International In-Touch Trial.
View abstractEffective, internationally transferable interventions for people with advanced dementia are needed to enhance consistent, high-quality care and quality of life. The international In-Touch project includes a cluster randomised controlled trial of an intervention to improve the quality of life for people with advanced dementia within nursing homes. A structured cultural adaptation process is crucial to ensure the In-Touch intervention retains core principles while improving local feasibility and acceptability, thereby enabling a clear assessment of fidelity. Here, we detail the cultural adaptation of the 'In-Touch Practical Guide for Nursing Home Staff' to enhance its feasibility, usability, and relevance across nursing homes in seven European countries. A structured cultural adaptation process, inspired by the ADAPT framework, was guided by an international team of experts, including individuals with lived experience, and dementia and palliative care researchers. Within-country group interviews were conducted in the Czech Republic, Ireland, Italy, Poland, Portugal, the Netherlands and the UK with three key participant groups: (1) nursing home staff familiar with intervention components, (2) nursing home staff unfamiliar with the intervention, and (3) family carers of people with advanced dementia. Participants ( = 97) evaluated the guide's clarity, cultural appropriateness, and feasibility. Cross-country consensus is presented here, with key themes including the need to simplify the guide to improve usability, ensure accessible language for all staff levels, and introduce discussion of flexibility in session length, structure, and available spaces to align with nursing home routines. Clearer guidance was needed on the roles of volunteers and family members. The guide was refined into a single, adaptable version, optimising its cultural relevance, usability, and practicality across diverse European settings. This collaborative adaptation process led to a culturally sensitive guide optimised for use in the In-Touch trial across Europe. The outlined methods can help adapt other interventions for future international palliative care research. |
Dementia (London, England) | 2026 Nov 14 | PubMed |
| 20 |
Economics of dementia care across five developed countries: A scoping review.
View abstractBackgroundAs the global population ages, the number of people living with dementia is rising rapidly, creating substantial economic challenges for healthcare systems, caregivers, and societies worldwide.ObjectiveWe examined the economics of dementia care across five developed countries to identify potentially transferable care practices and policy approaches relevant to the U.S.MethodsWe conducted a scoping review of studies involving adults with dementia that assessed dementia care, healthcare utilization, or costs in Canada, France, Germany, China, and Japan. Searches were performed in Ovid MEDLINE and Ovid Embase for January 2017-December 2023.ResultsOf 12,286 titles and abstracts screened, 266 articles underwent full-text review, and 63 met inclusion criteria. Studies were categorized into three areas: prescription drug use, direct medical costs, and economic impacts of care models or policies. We found that use of antidementia medications generally decreases with increasing dementia severity. Higher severity and greater burden of comorbidity were associated with increased costs, largely driven by frequent hospitalizations and long-term care. Policies incentivizing informal caregiving were associated with delayed long-term care but may reduce caregivers' labor-force participation, while in-kind, service-based models showed more consistent evidence of delaying costly institutional care. Evidence on integrated care models was mixed.ConclusionsRising dementia-related healthcare costs in aging populations represent a shared global challenge. Aligning reimbursement policies, care models, and service delivery with disease severity and care needs can improve efficiency, equity, and sustainability. |
Journal of Alzheimer's disease : JAD | 2026 Nov 14 | PubMed |
| 21 |
Potential synergy of cerebrospinal fluid TREM2 and BDNF/TrkB pathways promote mild depressive symptoms in Alzheimer's disease through tau pathology.
View abstractBackgroundEarly identification of Alzheimer's disease (AD) remains challenging. Mild depressive symptoms (MDSs) during the prodromal stage accelerate cognitive decline, but the underlying mechanisms remain unclear. Neuroinflammation and neurotrophic support are implicated in cognitive impairment, yet the interaction between triggering receptor expressed on myeloid cells 2 (TREM2)-mediated neuroimmune dysregulation and brain derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) deficits has not been established.ObjectiveThis study aimed to investigate whether alterations in cerebrospinal fluid (CSF) TREM2/sTREM2 and BDNF/TrkB interact to affect cognition in patients with AD and MDSs and whether tau pathology mediates this relationship, using observational data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).MethodsADNI data collected from 2005 to 2013 included 653 eligible participants. CSF TREM2, sTREM2, BDNF, TrkB, Aβ, pTau181, and tTau levels, neuropsychiatric measures, and cognitive scores were analyzed using analysis of covariance, stratified analyses, mediation analyses, and multivariable linear regression adjusted for age, sex, education, and ε4 status.ResultsCSF BDNF, TREM2, and sTREM2 levels varied significantly with age. sTREM2 appeared protective in early but not late disease stages. Reduced BDNF/TrkB signaling was associated with MDSs and poorer memory and executive function. Mediation analyses indicated that MDS-related cognitive impairment was partly mediated by TREM2/sTREM2-associated neuroinflammation and BDNF/TrkB dysfunction, particularly with elevated tau pathology.ConclusionsTREM2-mediated neuroimmune dysfunction and impaired BDNF/TrkB support may jointly exacerbate tau-related cognitive decline in preclinical AD with MDSs. This immune-neurotrophic interaction may promote dysfunctional microglial activation, excessive inflammation, and reduced clearance, offering a potential mechanism linking depressive symptoms to accelerated AD progression and informing early risk stratification and targeted intervention. |
Journal of Alzheimer's disease : JAD | 2026 Nov 14 | PubMed |
| 22 |
Integrated single-cell RNA sequencing and two-sample Mendelian randomization reveal CD4(+) T cell-expressed COMT and JUN as shared candidate genes for Alzheimer's disease and type 2 diabetes mellitus.
View abstractBackgroundAlzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are high-burden diseases; T2DM independently elevates AD risk via shared pathogenesis, yet their shared peripheral immune pathways and genetically supported cell-specific targets remain undefined.ObjectiveTo identify shared immune subsets, key genes and candidate compounds for AD and T2DM via integrated scRNA-seq and two-sample Mendelian randomization.MethodsWe constructed an integrated multi-omics framework combining peripheral blood mononuclear cell (PBMC) single-cell RNA sequencing (scRNA-seq) and two-sample Mendelian randomization (2SMR) using 10 public GEO datasets, with core analyses covering cell annotation, cell-cell communication profiling, differential expression analysis, eQTL-based 2SMR, in silico gene function prediction, and molecular docking with dynamics simulation for compound screening.ResultsCD4 T cells were inferred as the most abundant adaptive immune subset and a potential intercellular communication hub in peripheral blood of both AD and T2DM. Dual scRNA-seq/2SMR screening identified consistently upregulated shared candidate genes and , validated at single-cell and bulk transcriptome levels; myricetin and tauroursodeoxycholic acid were screened as candidate compounds with high predicted binding affinity to the encoded proteins. The 100 ns molecular dynamics simulation confirmed favorable structural stability of the -myricetin complex (RMSD ∼1.2 Å).ConclusionsAs an exploratory bioinformatics investigation, this study proposes a testable hypothesis that CD4 T cells and the / axis may act as a potential shared immune regulatory node in the concurrent pathogenesis of AD and T2DM, differing from the canonical T cell-driven pathological process in classic autoimmune diseases. All findings remain preliminary and require dedicated experimental validation. |
Journal of Alzheimer's disease : JAD | 2026 Nov 14 | PubMed |
| 23 |
Primary non-adherence to anti-dementia drugs, antidepressants, antipsychotics and benzodiazepines in individuals with dementia in Germany: A cohort study of primary care prescriptions.
View abstractBackgroundIndividuals with dementia frequently receive psychotropic and anti-dementia medication. Primary non-adherence (PNA), the failure to dispense a newly initiated medication, is an early and overlooked treatment barrier.ObjectiveTo estimate PNA at treatment initiation across four medication classes in dementia, to analyse subsequent prescriptions separately, and to identify associated patient factors.MethodsRetrospective cohort study using German primary care records linked to pharmacy dispensing data. Individuals aged 65 years and older with dementia who initiated anti-dementia drugs, antidepressants, antipsychotics, or benzodiazepines and related sedatives in general practices were included. Treatment initiation required 365 days of prior observation and no dispensing of the same class in that period. PNA was defined as failure to dispense within 30 days. Generalized estimating equations accounted for repeated observations within patients.ResultsAmong 10,746 initiations from 8634 individuals (mean age 83.4 years; 64.3% women), PNA occurred in 13.4% (95% CI 11.8-15.1) of anti-dementia drug, 11.5% (10.2-12.9) of antidepressant, 8.7% (7.9-9.5) of antipsychotic and 25.7% (23.8-27.7) of benzodiazepine initiations. Compared with antipsychotics, odds were higher for anti-dementia drugs (OR 1.54; 1.30-1.82), antidepressants (1.29; 1.11-1.51) and benzodiazepines (3.63; 3.14-4.20). Results were homogeneous across age cohorts (interaction p = 0.97). Among 180,796 subsequent prescriptions, non-dispensing was lower than at initiation except for benzodiazepines (31.5%).ConclusionsPNA at initiation was moderate for anti-dementia drugs, antidepressants and antipsychotics, and considerably higher for benzodiazepines and related sedatives. The latter warrants investigation into access barriers, preferences, safety concerns, and incomplete capture of privately issued prescriptions. |
Journal of Alzheimer's disease : JAD | 2026 Nov 14 | PubMed |
| 24 |
Association between empirical antibiotic appropriateness and clinical outcomes in surgically managed diabetic infections of the lower extremities: a retrospective cohort study.
View abstractBACKGROUND: Diabetic foot infections (DFIs) are a leading cause of hospitalization and lower-extremity amputations. Management requires combined surgical and antimicrobial treatment; however, the clinical impact of appropriate empirical antibiotic therapy remains uncertain. PATIENTS AND METHODS: We conducted a retrospective single-center study of hospitalized patients with DFI who underwent surgical debridement with positive deep tissue cultures. Patients were classified by appropriateness of empirical antimicrobial therapy administered. The primary outcome was a composite adverse outcome of major amputation, all-cause mortality, or ≥3 surgical procedures within 90 days. We also assessed hospitalization and antibiotic burden. Inverse probability of treatment weighting and multivariable regression were used to adjust for baseline differences and identify predictors of outcomes. RESULTS: We included 190 cases (mean age 64.9 ± 11.8 years; 24.2% female), of whom 57.9% received appropriate empirical therapy. Patients receiving inappropriate therapy had higher comorbidity burden and more prior vascular and diabetic foot complications. The primary outcome at 90 days was similar between groups (23.8% vs 21.8%; adjusted OR 0.64, 95% CI 0.23-1.76). On multivariable analysis, dementia, prior diabetic ulcer, and leukocytosis were associated with adverse outcomes, while empirical therapy appropriateness was not. Inappropriate therapy yielded fewer 30-day hospital-free and antibiotic-free days. CONCLUSION: In surgically managed DFIs without systemic illness, inappropriate empirical therapy - failing to cover all isolated pathogens - was not associated with worse 90-day clinical outcomes, though it reduced 30-day hospital-free and antibiotic-free days. Our findings support antimicrobial stewardship in DFIs, favoring narrow-spectrum empirical regimens following surgery while awaiting culture results. |
Annals of medicine | 2026 Dec | PubMed |
| 25 | Oral anticoagulation and cognitive outcomes in atrial fibrillation and Alzheimer's disease. | European heart journal | 2026 Nov 14 | PubMed |
| 26 | Undiagnosed dementia in underserved African American populations: Missed opportunities for care. | International psychogeriatrics | 2026 | Scholar |
| 27 | Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation | Alzheimer's Research & Therapy | 2026 | Scholar |
| 28 | Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA) | medRxiv | 2026 | Scholar |
| 29 | Decreased Length of Locus Coeruleus Norepinephrine Axons and Increased Amyloid Beta Pathology in Male APP/PS1 Mice During Protracted Abstinence From Alcohol | Neurotoxicity Research | 2026 | Scholar |
| 30 | Causes of death in patients with dementia: A study in a geriatric hospital in São Paulo, Brazil | Journal of Alzheimer's Disease | 2026 | Scholar |
| 31 | Annual Wellness Visits and Timing of Advance Care Planning Among Medicare Beneficiaries With Cognitive Impairment | Journal of the American Geriatrics Society | 2026 | Scholar |
| 32 | DNA Origami-Based Aptamers Targeting the Beta-secretase 1 (BACE1) Protein in Alzheimer’s Disease | 2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | 2026 | Scholar |
| 33 | Neuroinflammation in Alzheimer’s disease-associated sensory dysfunction: mechanistic links, actionable targets and therapeutic strategies | Frontiers in Aging Neuroscience | 2026 | Scholar |
| 34 | AI-Driven Detection of Alzheimer's Disease: Deep Learning for Identifying Four Stages of Dementia | 2026 9th International Conference on Intelligent Computing and Control Systems (ICICCS) | 2026 | Scholar |
| 35 | Neuropsychological profiles of dementia with lewy bodies according to alzheimer’s disease co-pathology | Alzheimer's Research & Therapy | 2026 | Scholar |
| 36 | Jejunal Diverticulitis With Contained Perforation and Abscess Successfully Managed With Conservative Therapy: A Case Report and Review of the Literature | Cureus | 2026 | Scholar |
| 37 | Multimodal neuroimaging in Alzheimer's disease: A practical, case-illustrated review of quantitative MRI and molecular PET. | Journal of Alzheimer's disease : JAD | 2026 | Scholar |
| 38 | Anti-Amyloid Drugs: Integrated Clinical Pathways for Treating Older Patients with Frailty and Dementia. | Ageing research reviews | 2026 | Scholar |

